# US 2014/0193514 A1 · Method for the Treatment of Cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193514 A1 - Document ID: US20140193514A1 - Status: Published application - Kind: A1 - Application number: 14/238,185 - Filed: 2012-08-16 - Published: 2014-07-10 - Earliest claimed: 2011-08-19 - Assignees: Marv Enterprises, LLC - Inventors: Mitchell S. Felder - Web page: https://patentgrep.com/patent/US20140193514A1 ## CPC - A61M 1/362: {changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity} - A61M 1/16: with membranes - A61M 1/3618: {Magnetic separation} - C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE} - A61M 1/3681: {by irradiation} - A61M 2205/75: with filters - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The invention describes a method to treat an extracorporeally body fluid. The body fluid can include, for example, blood, cerebral spinal fluid and lymph. A first stage of the method applies a treatment to the extracorporeal body fluid. The treatment comprises combining at least one antibody with a CA antigen to produce an antibody-CA antigen moiety. A second stage of the method substantially removes the antibody-CA antigen moiety from the extracorporeal body fluid. ## Claims ### Claim 1 A method for treating an extracorporeal body fluid comprising at least one CA antigen, the method characterized by: a) combining a first antibody with the CA antigen in the extracorporeal body fluid to produce an antibody-CA antigen moiety; and b) removing the antibody-CA antigen moiety from the extracorporeal body fluid. ### Claim 2 (depends on 1) The method of claim 1, wherein the CA antigen is selected from a group consisting of Angiogenesis (CA Ant. Ang.), Tumorigenesis (CA Ant. T.), Signal Transducer (CA Ant. ST), carcinoma specific antigens (CA Ant. Sp.), antigens which decrease chemotherapeutic efficacy (CA Ant. Chem.), and combinations thereof. ### Claim 3 (depends on 1) The method of claim 1, characterized by removing the antibody-CA antigen moiety includes irradiation, magnetism, mechanical filtering, chemical filtering, and combinations thereof. ### Claim 4 (depends on 1) The method of claim 1, further characterized by conjugating the antibody-CA antigen with albumin thereby forming an albumin-antibody-CA antigen compound. ### Claim 5 (depends on 1) The method of claim 1 further characterized by testing the extracorporeal body fluid for efficacy of removing the antibody-CA antigen moiety. ### Claim 6 (depends on 1) The method of claim 1 further characterized by removing a body fluid from a patient to produce the extracorporeal body fluid and returning the extracorporeal body fluid to the patient after treating the extracorporeal body fluid. ### Claim 7 (depends on 1) The method of claim 1, characterized by combining the first antibody with the CA antigen in a first stage, passing the extracorporeal body fluid to a second stage, and removing the antibody-CA antigen moiety from the body fluid in the second stage. ### Claim 8 (depends on 7) The method of claim 7, characterized by providing a filtering machine comprising the first stage and the second stage, and sequentially passing the extracorporeal body fluid through the first and second stages. ### Claim 9 (depends on 7) The method of claim 7, characterized by conjugating the antibody-CA antigen with albumin in the first stage, thereby forming an albumin-antibody-CA antigen compound. ### Claim 10 (depends on 1) The method of claim 1, characterized by conjugating the antibody-CA antigen with a designer antibody comprising an attached macromolecular moiety, thereby forming an antibody-macromolecular moiety-targeted antigen complex having a diameter. ### Claim 11 (depends on 10) The method of claim 10, characterized by the diameter of the antibody-macromolecular moiety-targeted antigen complex being from about 0.905 mm to 1,000 mm. ### Claim 12 (depends on 10) The method of claim 10, characterized by removing the antibody-macromolecular moiety-targeted antigen complex by filtering through at least one screen filter defining a plurality of openings having opening diameters less than the diameter of the antibody macromolecular moiety-targeted antigen complex. ### Claim 13 (depends on 12) The method of claim 12, characterized by the opening diameters being 50% to 99% of the diameter of the antibody-macromolecular moiety-targeted antigen complex. ### Claim 14 (depends on 12) The method of claim 12, characterized by the opening diameters being at least 25 micrometers. ### Claim 15 (depends on 1) The method of claim 1, characterized by the first antibody being fixed to an antibody microarray, whereby removing the antibody-CA antigen moiety from the extracorporeal body fluid comprises fixing the antibody-CA antigen moiety to the microarray. ### Claim 16 (depends on 1) The method of claim 1, characterized by combining the antibody-CA antigen moiety with at least one antibody containing iron, thereby forming an Fe-Antibody-Antigen complex, and removing the Fe-Antibody-Antigen complex using a strong, localized magnetic field. ### Claim 17 (depends on 1) The method of claim 1, characterized by removing the antibody-CA antigen moiety using Kanzius radiofrequency (RF) therapy and removing residue of the Kanzius radiofrequency (RF) therapy from the extracorporeal body fluid. ### Claim 18 (depends on 1) The method of claim 1, characterized by removing the antibody-CA antigen moiety using a molecular filter. ### Claim 19 (depends on 1) The method of claim 1, characterized by removing the antibody-CA antigen moiety using a molecular sieve comprising a material selected from a group consisting of zeolite, polyacrylonitrile, polysulfone, polyamide, cellulose, cellulose acetate, polyacrylate, polymethylmethacrylate, and combinations thereof. ### Claim 20 (depends on 1) The method of claim 1, further characterized by retreating the extracorporeal body fluid if an unacceptably large concentration of antibody-CA antigen moiety remains in the extracorporeal body fluid.